Інформація опублікована з довідковою метою і не є рекламою, офертою, публічною пропозицією або керівництвом до застосування. Представлена виключно для інформування наших пацієнтів, які перебувають за кордоном. Сайт не здійснює жодної дистанційної торгівлі. Продаж, розповсюдження, доставка та призначення товарів через веб-ресурс не провадяться. Застосування товарів та медичних послуг можливе виключно за призначенням лікаря. Консультації надаються фахівцями клініки у очному форматі або за допомогою дистанційної медичної консультації у рамках чинного законодавства. Прошу звернути Вашу увагу, що у цьому довіднику продаж товарів програмно не передбачено.
Cervarix is a vaccine against the human papillomavirus (HPV). It protects against two highly oncogenic types of HPV — 16 and 18, which cause about 70% of cervical cancer cases.
🔹 Types of HPV covered
• 16 — the most oncogenic
• 18 — second in significance
There is also cross-protection (not 100%, but significant) against types 31, 33, and 45, which increases the actual protection to about 80–85% of cervical cancer cases.
🔹 What it protects against
• Cervical cancer
• Some precancerous conditions (CIN2/3)
• To a lesser extent — anal canal cancer (indirectly)
Cervarix does not protect against genital warts (as they are caused by types 6 and 11, which are not included in the vaccine).
🔹 Recommended for
• Girls and women aged 9 to 25 years (ideally before the onset of sexual activity).
• It can also be used later (up to 45 years) — at the discretion of a doctor.
🔹 Effectiveness
• Against HPV 16 and 18: ≈95–100% when vaccinated before infection
• Cross-protection: 30–60% against types 31/33/45
• Reduction in cervical cancer risk in countries with mass vaccination: ≈70–80%
🔹 Side effects (usually mild)
• Pain at the injection site
• Fever
• Weakness
• Headache
Serious reactions are extremely rare.
🔹 Types of HPV covered
• 16 — the most oncogenic
• 18 — second in significance
There is also cross-protection (not 100%, but significant) against types 31, 33, and 45, which increases the actual protection to about 80–85% of cervical cancer cases.
🔹 What it protects against
• Cervical cancer
• Some precancerous conditions (CIN2/3)
• To a lesser extent — anal canal cancer (indirectly)
Cervarix does not protect against genital warts (as they are caused by types 6 and 11, which are not included in the vaccine).
🔹 Recommended for
• Girls and women aged 9 to 25 years (ideally before the onset of sexual activity).
• It can also be used later (up to 45 years) — at the discretion of a doctor.
🔹 Effectiveness
• Against HPV 16 and 18: ≈95–100% when vaccinated before infection
• Cross-protection: 30–60% against types 31/33/45
• Reduction in cervical cancer risk in countries with mass vaccination: ≈70–80%
🔹 Side effects (usually mild)
• Pain at the injection site
• Fever
• Weakness
• Headache
Serious reactions are extremely rare.
